Home  /  Resource Library  /  Efficacy of BTK inhibitor combined with rituximab and lenalidomide in newly diagnosed diffuse large B-cell lymphoma: a single-center, retrospective study

Efficacy of BTK inhibitor combined with rituximab and lenalidomide in newly diagnosed diffuse large B-cell lymphoma: a single-center, retrospective study

Retrospective study examined zanubrutinib or orelabrutinib combined with rituximab and lenalidomide for first line treatment of DLBCL.